Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    20222977 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Completed TLK286 in Combination With Doxil in Platinum Refractory or Resistant Ovarian Cancer
Condition: Ovarian Neoplasms
Intervention: Drug: TLK286

Indicates status has not been verified in more than two years